Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon therapy in hepatitis C

N N Zein1, J Rakela

  • 1Department of Medicine, Mayo Clinic and Foundation, Rochester, MN.

Seminars in Gastrointestinal Disease
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

De Novo Autoimmune Hepatitis Following Liver Transplantation.

Transplantation proceedings·2018
Same author

Liver Transplantation for Hepatitis B in Early Adulthood: Analysis of the United Network for Organ Sharing Database.

Transplantation proceedings·2016
Same author

Sofosbuvir and Simeprevir for the Treatment of Recurrent Hepatitis C with Fibrosing Cholestatic Hepatitis after Liver Transplantation.

International journal of organ transplantation medicine·2016
Same author

Treatment of Recurrent Hepatitis C Genotype-4 Post-Liver Transplantation with Sofosbuvir plus Simeprevir.

International journal of organ transplantation medicine·2015
Same author

Monitoring serial CD4⁺ T-cell function after liver transplantation can be used to predict hepatocellular carcinoma recurrence.

Transplantation proceedings·2015
Same author

IL-2 Receptor Antagonist (Basiliximab) Is Associated with Rapid Fibrosis Progression in Patients with Recurrent Hepatitis C after Liver Transplantation Using Serial Biopsy Specimens.

International journal of organ transplantation medicine·2014

Interferon effectively treats chronic hepatitis C, but its use in acute hepatitis C virus (HCV) infection requires further study. Patient selection and optimized interferon dosage/duration are key for better outcomes in HCV treatment.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Interferon is an established treatment for chronic hepatitis C infection.
  • Its efficacy in acute hepatitis C virus (HCV) infection is not yet fully established.
  • Current treatment guidelines recommend 3 MU thrice weekly, but higher doses or longer durations may offer benefits.

Purpose of the Study:

  • To review the current understanding of interferon therapy for hepatitis C.
  • To identify factors influencing treatment response.
  • To highlight areas needing further research, particularly for acute HCV and pediatric populations.

Main Methods:

  • Literature review of existing studies on interferon for hepatitis C.
  • Analysis of factors affecting treatment outcomes, including viral load, genotype, and liver disease severity.

Related Experiment Videos

  • Identification of knowledge gaps in current therapeutic recommendations.

    • Main Results:

    • Interferon effectiveness is demonstrated in chronic HCV but requires more investigation for acute HCV.
    • Patient selection based on factors like inflammation, fibrosis, HCV-RNA titer, and genotype can improve response rates and cost-effectiveness.
    • No controlled studies have assessed interferon use in children with chronic HCV infection.

    Conclusions:

    • Further research is needed to establish optimal interferon regimens for acute HCV infection.
    • Personalized patient selection is crucial for maximizing interferon treatment efficacy and cost-effectiveness.
    • Enrollment of patients, especially children with chronic HCV, in clinical trials is recommended to address unanswered questions regarding interferon therapy.